Arcellx

Chairman and CEO Rami Elghandour brought public company operating experience and scaled the team to a registrational and pre‑commercial posture, while aligning with Kite’s proven cell‑therapy operators.

Clinical execution and IR cadence around ASH/EHA were consistent, culminating in a BLA filing accepted in February 2026. The leadership made pragmatic choices to leverage Kite’s manufacturing and center network rather than attempting greenfield buildouts.

The acquisition outcome suggests credible stewardship, although long‑term strategic control now resides with Gilead.